Literature DB >> 8970399

Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease.

H A Kerstjens1, P L Brand, D S Postma.   

Abstract

The interpretation of studies of decline of FEV1 in patients with established COPD is complicated by many methodologic problems, such as retrospective analyses, small patient groups, different patient selection, and differences in the mathematical models used. Nevertheless, it is clear that the rate of loss of lung function is above all determined by the smoking status and history. A more abnormal bronchoconstrictor response is predictive of a steeper decline of lung function. Other prognostic factors have not been consistently found in patients with established disease. The decline can be influenced favorably by smoking cessation, and probably by oxygen administration in hypoxemic patients. Long-term oral steroid use seems to be associated with a more favorable course of FEV1, but the value of inhaled corticosteroids has not yet been established. Maintenance therapy with bronchodilators only does not appear to improve the decline of FEV1.

Entities:  

Mesh:

Year:  1996        PMID: 8970399     DOI: 10.1164/ajrccm/154.6_Pt_2.S266

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

Review 1.  Stable chronic obstructive pulmonary disease.

Authors:  H A Kerstjens
Journal:  BMJ       Date:  1999-08-21

Review 2.  [Chronic bronchitis, COPD].

Authors:  H R Wirtz
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

3.  Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.

Authors:  D G Parr; B C Stoel; J Stolk; R A Stockley
Journal:  Thorax       Date:  2006-03-14       Impact factor: 9.139

Review 4.  Decline of FEV1 by age and smoking status: facts, figures, and fallacies.

Authors:  H A Kerstjens; B Rijcken; J P Schouten; D S Postma
Journal:  Thorax       Date:  1997-09       Impact factor: 9.139

5.  Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS.

Authors:  S J Gange; A Muñoz; J S Chmiel; A D Donnenberg; L M Kirstein; R Detels; J B Margolick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

6.  Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.

Authors:  G T Verhoeven; J P J J Hegmans; P G H Mulder; J M Bogaard; H C Hoogsteden; J-B Prins
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

7.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; P S Burge; S Spencer; J A Anderson; P W Jones
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

Review 8.  [Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease].

Authors:  Adrian Gillissen; Thomas Glaab; Roland Buhl
Journal:  Med Klin (Munich)       Date:  2009-02-26

Review 9.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

10.  Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.

Authors:  Douglas W Mapel; Michael P Dutro; Jeno P Marton; Kimberly Woodruff; Barry Make
Journal:  BMC Health Serv Res       Date:  2011-02-23       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.